pharmaphorum8d
A history of Bayer
Dr. Marijn Dekkers, Bayer chief executive, 2010-2016 However, before we get into the history of this German pharmaceutical company ... own Bayer Cross corporate logo. This was under the leadership ...
BioPharma Dive14h
Eisai wins over European regulators on Alzheimer’s drug Leqembi
A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...
Eisai Gets Positive Opinion From CHMP In European Union For Lecanemab In Early Alzheimer's Disease
Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...
European committee takes a second look at Alzheimer's drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer's treatment lecanemab a few months after rejecting ...
Investing4d
Earnings call: Eisai reports growth with focus on Alzheimer's treatment
Eisai Company Limited (4523.T) has reported a modest revenue increase in its Q2 Fiscal 2024 earnings call, with significant developments in its Alzheimer's disease treatments. The pharmaceutical ...
Investing4d
Earnings call: Eisai reports growth with focus on Alzheimer's treatment
Eisai Company Limited (4523.T) has reported a modest revenue increase in its Q2 Fiscal 2024 earnings call, with significant developments in its Alzheimer's disease treatments. The pharmaceutical giant ...
Investing3d
Earnings call: Eisai reports steady growth and LEQEMBI launch success
Eisai Company Limited (ESALY (OTC:ESAIY)) has reported a modest revenue growth of 3% year-on-year in its Q2 Fiscal 2024 earnings call, totaling JPY 385 billion. The pharmaceutical segment saw a 5% ...
Investing3d
Earnings call: Eisai reports steady growth and LEQEMBI launch success
Eisai Company Limited (ESALY (OTC:ESAIY)) has reported a modest revenue growth of 3% year-on-year in its Q2 Fiscal 2024 earnings call, totaling JPY 385 billion. The pharmaceutical segment saw a 5% ...
Asia One10d
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
The company also supports investment in drug discovery technologies in other areas, where significant future innovations are anticipated. As anAMED-registered VC, Eisai Innovation, Inc. aims to ...
Morningstar7d
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion
STOCKHOLM, Nov. 7, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated ... is a Swedish research-based biopharma company focusing on innovative ...
Yahoo Finance7d
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion
STOCKHOLM, Nov. 8, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs ...